IRIS
PASQUINUCCI, Lorella Giuseppina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.580
EU - Europa 2.423
AS - Asia 1.976
AF - Africa 388
SA - Sud America 354
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.732
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.417
IT - Italia 1.139
SG - Singapore 902
CN - Cina 785
IE - Irlanda 415
BR - Brasile 321
UA - Ucraina 278
CI - Costa d'Avorio 237
DE - Germania 166
CA - Canada 144
SN - Senegal 119
RU - Federazione Russa 114
KR - Corea 103
FR - Francia 44
GB - Regno Unito 39
IN - India 37
ES - Italia 35
JP - Giappone 35
FI - Finlandia 34
SE - Svezia 34
NL - Olanda 25
BE - Belgio 21
PL - Polonia 18
BD - Bangladesh 17
VN - Vietnam 17
AT - Austria 14
TR - Turchia 14
AR - Argentina 10
AU - Australia 10
CH - Svizzera 10
CZ - Repubblica Ceca 10
UZ - Uzbekistan 10
ZA - Sudafrica 10
IR - Iran 9
MX - Messico 9
GR - Grecia 8
HU - Ungheria 7
PK - Pakistan 7
AE - Emirati Arabi Uniti 6
IQ - Iraq 6
VE - Venezuela 6
CO - Colombia 5
EC - Ecuador 5
ID - Indonesia 5
LB - Libano 5
MA - Marocco 5
TN - Tunisia 5
BG - Bulgaria 4
HK - Hong Kong 4
KE - Kenya 4
NG - Nigeria 4
IL - Israele 3
JM - Giamaica 3
KZ - Kazakistan 3
SA - Arabia Saudita 3
BB - Barbados 2
CL - Cile 2
DO - Repubblica Dominicana 2
EG - Egitto 2
GE - Georgia 2
LT - Lituania 2
PE - Perù 2
RS - Serbia 2
AZ - Azerbaigian 1
BO - Bolivia 1
CR - Costa Rica 1
DK - Danimarca 1
DZ - Algeria 1
EU - Europa 1
IM - Isola di Man 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
SL - Sierra Leone 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 9.732
Salva come PNG Salva come JPEG
Città #
Santa Clara 764
Chandler 591
Singapore 544
Houston 471
Dublin 412
Chicago 334
Catania 332
Jacksonville 286
Abidjan 237
Hefei 210
Ashburn 190
Boardman 188
Dakar 119
Nanjing 116
Cambridge 110
Andover 109
Lawrence 109
Beijing 104
Seoul 103
Civitanova Marche 98
Toronto 95
Council Bluffs 62
Bremen 60
Wilmington 57
Rome 54
Des Moines 50
San Mateo 47
The Dalles 45
Columbus 39
Naples 38
Los Angeles 37
Grafing 36
Munich 35
Shenyang 35
Nanchang 33
Saint Petersburg 32
São Paulo 28
Tokyo 28
Changsha 26
Jiaxing 25
New York 25
Ottawa 25
Messina 22
Hebei 21
Brussels 20
Tianjin 19
Pune 17
Moscow 16
Rio de Janeiro 16
Falls Church 15
Milan 14
San Giovanni la Punta 14
Turku 14
Seattle 13
Dallas 12
San Francisco 12
Dong Ket 11
Helsinki 11
Augusta 10
Ningbo 10
Norwalk 10
Pozzallo 10
Brooklyn 9
Jinan 9
Lappeenranta 9
Madrid 9
Palermo 9
Rimini 9
Sala Baganza 9
Salerno 9
Warsaw 9
Ardabil 8
Bari 8
Bologna 8
Leawood 8
Montreal 8
Paris 8
Paternò 8
Amsterdam 7
Belo Horizonte 7
Brno 7
Budapest 7
Marseille 7
Melbourne 7
Monmouth Junction 7
Tappahannock 7
Washington 7
Atlanta 6
Cagliari 6
Dearborn 6
Den Haag 6
Fukuoka 6
Gravina di Catania 6
Guangzhou 6
Lentini 6
London 6
Misterbianco 6
Phoenix 6
San Gregorio di Catania 6
Santiago de Compostela 6
Totale 6.904
Salva come PNG Salva come JPEG
Nome #
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 382
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 218
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 144
Antioxidant properties and pharmacokinetic studies of new selective σ1 bifunctional ligands 135
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 134
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 124
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells 116
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 113
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 110
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 103
Design of Small Molecules for Oncological and Neurodegenerative Diseases 101
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 100
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 99
From plant to bench: natural products as source for analgesic drug development. 98
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma 98
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 95
Intercellular communication and ion channels in neuropathic pain chronicization 95
Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist 94
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 91
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 89
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 89
CCB, a novel specific kappa opioid agonist, which discriminates between opioid and sigma 1 recognition sites 88
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 88
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 87
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 87
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 86
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation 86
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 85
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 85
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 83
CCB - A novel analog of MPCB with high binding affinity and specific kappa opioid receptor agonist 83
(+)-cis-N-ethyleneamino-N-normetazocine derivatives. Novel and selective sigma ligands with antagonist properties 83
Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands 82
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 82
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 81
Multitarget opioid ligands in pain relief: New players in an old game 80
Benzomorphan-based opioid ligands with mixed m agonist/d antagonist activity 80
Analgesici oppioidi: nuove opportunità nella terapia del dolore 80
Non-peptide ligands for opioid receptors. Design of kappa-specific agonists 79
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 79
SYNTHESIS OF (+)-(1'R,2'S) AND (1'S,2'R)-6,11-DIMETHYL-1,2,3,4,5,6-HEXAHYDRO-3-[[2'-(ALKOXYCARBONYL)-2'-PHENYLCYCLOPROPYL]METHYL]-2,6-METHANO-3-BENZAZOCIN-8-OL. COMPARISON OF THE AFFINITIES FOR SIGMA 1 AND OPIOID RECEPTORS WITHIN THE DIASTEREOISOMERIC MPCB AND CCB 78
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 78
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 77
Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 77
Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites 77
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 76
Bivalent opioid-peptides synthesized from mu-selective monomers display preferential selectivity for delta-receptors 76
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 76
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 75
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 75
Design and synthesis of trans-decahydroisoquinoline derivatives as new tramadol-like ligands 75
Differential scanning calorimetry approach to investigate the transfer of the multitarget opioid analgesic LP1 to biomembrane model 74
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 74
Nonpeptide Analogues of Dynorphin A(1-8): Design, Synthesis, and Pharmacological Evaluation of k-Selective Agonists 73
MOR/DOR targeting: an useful strategy in pain management 73
Bivalent opioid peptides synthesized from μ selective monomers display preferential selectivity for δ receptors 73
From agonist to antagonist profile in LP1 analogues through the introduction of different N-substituents in benzomorphan-based ligands 72
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 71
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 71
Progress in the development of more effective and safer analgesics for pain management 71
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 69
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 68
The blockade of NOP receptor in the vlPAG reduces the development of tolerance to opioid-induced antinociception in rats 68
Multitarget opioid ligands as suitable candidates for pain management Pharmacolgical fingerprint of the benzomorphan-based opioid compound LP1 68
New developments in opioid receptors ligands 67
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 67
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 67
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 66
In-vitro evaluation of a new benzomorphan-based ligand 66
Development of new benzomorphan LP1 analogues 65
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 65
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 64
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 64
Dual-target ligands and pain: our experience 63
Synthesis and Pharmacological Evaluation of Peptidomimetic of the Kappa-Opioid Receptors 63
Analoghi non-peptidici della dinorfina A(1-8): progettazione, sintesi e valutazione farmacologica di agonisti ad elevata selettività Kappa. 63
Modulation of opioid receptor profile of LP1 analogues through the introduction of different N-substituents 63
Idebenone: Novel strategies to improve its systemic and local efficacy 63
From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design 62
Specific kappa opioid receptor agonists 62
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 62
Designing drugs optimized for both blood-brain barrier permeation and intra-cerebral partition 61
Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands 61
Novel methyl-2-[4-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-phenylcyclopropane-carboxylate derivatives as sigma-1 and sigma-2 receptor ligands 61
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation 59
In vitro evaluation of new benzomorphan-based ligands 59
Evaluation of N-substitution in 6,7-benzomorphan compounds 59
Synthesis of substituted pyrimidines, pyrazole[3,4-d]pyrimidines and imidazo[4,5-d]pyrimidines and evaluation of their antifungal activity 59
New bifunctional antioxidant/σ1 agonist ligands: preliminary chemico-physical and biological evaluation 58
Glycopeptide- and carbohydrate-based synthetic vaccines for cancer immunotherapy 58
INTERACTION OF A NEW ANALGESIC AGENT, LP1, WITH THE BIOMEMBRANE MODELS: CALORIMETRIC STUDY 58
Pain management: new long-acting opioid ligands 58
Design, Synthesis and biological evaluation of hybrid MOR agonist/ HDACi molecules as potential therapeutic agents for chronic pain treatment 57
Analgesici oppioidi 57
Synthesis and pharmacological properties of N-thienyl alkylenediamines 57
New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands 57
Multitarget MOR/DOR antinociceptive ligands as useful profile in pain management: synthesis and pharmacological studies of 6,7-benzomorphan-based LP2 and its isomers 57
Design and synthesis of new bifunctional sigma-1 selective ligands with antioxidant activity. 56
Resveratrol-loaded lipid nanocarriers: Correlation between in vitro occlusion factor and in vivo skin hydrating effect 56
Simultaneous activation of mu and delta opioid receptors reduces allodynia and astrocytic connexin 43 in an animal model of neuropathic pain 56
Totale 8.173
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.417
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.417
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021638 0 47 71 18 167 18 64 6 85 13 114 35
2021/2022934 100 105 9 24 135 11 120 34 84 26 36 250
2022/20231.774 140 97 29 239 132 267 6 344 365 35 80 40
2023/20241.092 55 138 51 40 56 262 67 111 8 30 188 86
2024/20253.397 83 520 150 227 665 426 231 137 219 263 226 250
2025/2026799 473 326 0 0 0 0 0 0 0 0 0 0
Totale 10.066